Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Loymaxi is a branded generic fixed-dose combination product marketed by Lloyd Healthcare, an Indian pharmaceutical company, for use in orthopedic and musculoskeletal care. The formulation typically contains methylcobalamin (1500 mcg), alpha-lipoic acid (100 mg), pyridoxine (3 mg), and folic acid (1.5 mg). It is primarily indicated for the management of peripheral neuropathy, radiculopathy, and other musculoskeletal conditions where nerve health and oxidative stress are concerns. Methylcobalamin, a bioactive form of Vitamin B12, supports nerve regeneration and myelin sheath maintenance. Alpha-lipoic acid acts as a potent antioxidant to protect neural tissues from oxidative damage. Pyridoxine and folic acid serve as essential cofactors for metabolic processes and DNA synthesis. Loymaxi is commercially available in India as an oral formulation.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Loymaxi.